SCHEMBL2227226

SCHEMBL2227226

Clc1cccc2cc(OCC3CCNC3)ccc12

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.70
SLC6A4 P31645 6/20 0.70
SLC6A3 Q01959 3/20 0.70
HTR3A P46098 2/20 0.58
KCNH2 Q12809 2/20 0.58
MAP2K1 Q02750 2/20 0.54
PRKCZ Q05513 2/20 0.47
CHEK1 O14757 1/20 0.44
CHEK2 O96017 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
TDP1 Q9NUW8 1/20 0.41
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
PARP15 Q460N3 1/20 0.39
PARP10 Q53GL7 1/20 0.39
KHK P50053 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13837549 0.85 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2228515 0.83 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2227832 0.83 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2227826 0.83 SLC6A2 (1.00) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL31071592 0.79 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2230447 0.76 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL17848466 0.75 SLC6A2 (0.61) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL13107018 0.75 SLC6A2 (0.84) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2229867 0.73 SLC6A2 (0.71) SLC6A2SLC6A4SLC6A3HTR3AKCNH2
SCHEMBL2362924 0.73 SLC6A4 (0.56) SLC6A2SLC6A4SLC6A3HTR3AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 SLC6A2 2876/4885SLC6A4 3841/4885SLC6A3 2474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.